Compare Orchid Chemicals with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CIPLA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CIPLA ORCHID PHARMA LTD/
CIPLA
 
P/E (TTM) x -0.5 23.8 - View Chart
P/BV x 0.1 2.4 4.9% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   CIPLA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CIPLA
Mar-19
ORCHID PHARMA LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs194678 28.6%   
Low Rs35484 7.2%   
Sales per share (Unadj.) Rs276.5198.2 139.5%  
Earnings per share (Unadj.) Rs-79.218.5 -427.6%  
Cash flow per share (Unadj.) Rs-43.535.0 -124.2%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9186.3 28.9%  
Shares outstanding (eoy) m70.45805.70 8.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.9 14.1%   
Avg P/E ratio x-1.431.4 -4.6%  
P/CF ratio (eoy) x-2.616.6 -15.9%  
Price / Book Value ratio x2.13.1 68.1%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m8,067468,031 1.7%   
No. of employees `0002.822.6 12.4%   
Total wages/salary Rs m2,52728,565 8.8%   
Avg. sales/employee Rs Th6,956.17,053.1 98.6%   
Avg. wages/employee Rs Th902.51,261.5 71.5%   
Avg. net profit/employee Rs Th-1,993.0659.1 -302.4%   
INCOME DATA
Net Sales Rs m19,477159,710 12.2%  
Other income Rs m4074,766 8.5%   
Total revenues Rs m19,884164,475 12.1%   
Gross profit Rs m1,10330,973 3.6%  
Depreciation Rs m2,51913,263 19.0%   
Interest Rs m5,2271,684 310.3%   
Profit before tax Rs m-6,23620,791 -30.0%   
Minority Interest Rs m20-172 -11.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1255,695 -2.2%   
Profit after tax Rs m-5,58014,924 -37.4%  
Gross profit margin %5.719.4 29.2%  
Effective tax rate %2.027.4 7.3%   
Net profit margin %-28.79.3 -306.6%  
BALANCE SHEET DATA
Current assets Rs m11,014124,266 8.9%   
Current liabilities Rs m32,06037,715 85.0%   
Net working cap to sales %-108.154.2 -199.4%  
Current ratio x0.33.3 10.4%  
Inventory Days Days9591 104.7%  
Debtors Days Days3495 35.4%  
Net fixed assets Rs m29,440105,190 28.0%   
Share capital Rs m7051,611 43.7%   
"Free" reserves Rs m2,043148,511 1.4%   
Net worth Rs m3,800150,123 2.5%   
Long term debt Rs m9,01838,301 23.5%   
Total assets Rs m46,510239,633 19.4%  
Interest coverage x-0.213.3 -1.4%   
Debt to equity ratio x2.40.3 930.2%  
Sales to assets ratio x0.40.7 62.8%   
Return on assets %-0.86.9 -11.0%  
Return on equity %-146.99.9 -1,477.2%  
Return on capital %-3.711.8 -31.6%  
Exports to sales %37.934.7 109.2%   
Imports to sales %22.60-   
Exports (fob) Rs m7,37855,419 13.3%   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51357,410 13.1%   
Fx outflow Rs m5,64919,041 29.7%   
Net fx Rs m1,86538,368 4.9%   
CASH FLOW
From Operations Rs m1,68216,911 9.9%  
From Investments Rs m-9,860-16,687 59.1%  
From Financial Activity Rs m6,644-3,487 -190.5%  
Net Cashflow Rs m-1,535-3,451 44.5%  

Share Holding

Indian Promoters % 32.3 16.0 201.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.6 12.2 37.7%  
FIIs % 3.3 23.7 13.9%  
ADR/GDR % 4.6 1.1 418.2%  
Free float % 55.3 26.2 211.1%  
Shareholders   84,811 161,166 52.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Strong; HCL Tech and Tech Mahindra Top Gainers(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.6% while the Hang Seng is up 0.4%.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

My Top 10 Stocks for Accelerated Profits

Oct 18, 2019

Equitymaster's co-head of research and editor of Microcap Millionaires, Rahul Shah, talks to us about his market-beating system and his 10 best stocks to buy now. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS